289 related articles for article (PubMed ID: 36430148)
21. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
Jelinic P; Schlappe BA; Conlon N; Tseng J; Olvera N; Dao F; Mueller JJ; Hussein Y; Soslow RA; Levine DA
Mod Pathol; 2016 Jan; 29(1):60-6. PubMed ID: 26564006
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer.
Leitner K; Tsibulak I; Wieser V; Knoll K; Reimer D; Marth C; Fiegl H; Zeimet AG
Sci Rep; 2020 Nov; 10(1):20412. PubMed ID: 33230143
[TBL] [Abstract][Full Text] [Related]
23. SMARCA4-deficient undifferentiated carcinoma of the ovary (small cell carcinoma, hypercalcemic type): clinicopathologic and immunohistochemical study of 3 cases.
Agaimy A; Thiel F; Hartmann A; Fukunaga M
Ann Diagn Pathol; 2015 Oct; 19(5):283-7. PubMed ID: 26123103
[TBL] [Abstract][Full Text] [Related]
24. SMARCA4 loss irrelevant for
Wagner SK; Moon AS; Howitt BE; Renz M
Gynecol Oncol Rep; 2023 Dec; 50():101305. PubMed ID: 38033359
[TBL] [Abstract][Full Text] [Related]
25. SWI/SNF-deficient malignancies of the female genital tract.
McCluggage WG; Stewart CJR
Semin Diagn Pathol; 2021 May; 38(3):199-211. PubMed ID: 32978032
[TBL] [Abstract][Full Text] [Related]
26. [Chromatin remodeling defects and cancer: the SWI/SNF example].
Bourdeaut F; Bièche I
Bull Cancer; 2012 Dec; 99(12):1133-40. PubMed ID: 23222069
[TBL] [Abstract][Full Text] [Related]
27. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
28. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
29. [Pathological and molecular features of malignancies underlined by BAF complexes inactivation].
Le Quang M; Ranchère-Vince D; Le Loarer F
Ann Pathol; 2019 Dec; 39(6):399-413. PubMed ID: 31255411
[TBL] [Abstract][Full Text] [Related]
30. SWI/SNF chromatin remodeling complexes and cancer.
Biegel JA; Busse TM; Weissman BE
Am J Med Genet C Semin Med Genet; 2014 Sep; 166C(3):350-66. PubMed ID: 25169151
[TBL] [Abstract][Full Text] [Related]
31. Genetic variant in SWI/SNF complexes influences hepatocellular carcinoma risk: a new clue for the contribution of chromatin remodeling in carcinogenesis.
Zhong R; Liu L; Tian Y; Wang Y; Tian J; Zhu BB; Chen W; Qian JM; Zou L; Xiao M; Shen N; Yang H; Lou J; Qiu Q; Ke JT; Lu XH; Wang ZL; Song W; Zhang T; Li H; Wang L; Miao XP
Sci Rep; 2014 Feb; 4():4147. PubMed ID: 24556940
[TBL] [Abstract][Full Text] [Related]
32. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
33. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
34. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
Medina PP; Sanchez-Cespedes M
Epigenetics; 2008; 3(2):64-8. PubMed ID: 18437052
[TBL] [Abstract][Full Text] [Related]
35. The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer.
Wu Q; Lian JB; Stein JL; Stein GS; Nickerson JA; Imbalzano AN
Epigenomics; 2017 Jun; 9(6):919-931. PubMed ID: 28521512
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma.
Bennett JA; Safdar N; Segal JP; Lastra RR; Oliva E
Int J Gynecol Pathol; 2021 Mar; 40(2):156-164. PubMed ID: 32897960
[TBL] [Abstract][Full Text] [Related]
37. Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5.
Gao H; Lukin K; Ramírez J; Fields S; Lopez D; Hagman J
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11258-63. PubMed ID: 19549820
[TBL] [Abstract][Full Text] [Related]
38. The SWI/SNF ATP-Dependent Chromatin Remodeling Complex in Arabidopsis Responds to Environmental Changes in Temperature-Dependent Manner.
Gratkowska-Zmuda DM; Kubala S; Sarnowska E; Cwiek P; Oksinska P; Steciuk J; Rolicka AT; Zaborowska M; Bucior E; Maassen A; Franzen R; Koncz C; Sarnowski TJ
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979421
[TBL] [Abstract][Full Text] [Related]
39. Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines.
Kimura A; Arakawa N; Hirano H
J Proteome Res; 2014 Nov; 13(11):4959-69. PubMed ID: 25083560
[TBL] [Abstract][Full Text] [Related]
40. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
